Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer's disease
Sanofi-aventis, Innogenetics, and Inserm, through its subsidiary called Inserm Transfert, announced the conclusion of a collaborative research agreement in the field of Alzheimer's disease. This collaboration agreement is signed for an initial period of 2 years, with an option for Sanofi-aventis to obtain an exclusive worldwide license on the results arising from the research program in the therapeutics field. Innogenetics will have an exclusive worldwide license in the diagnostics field.
The present agreement is built on intellectual property and a research collaboration between Innogenetics and Inserm-Lille (U-422) on the development of new diagnostic tools for Alzheimer's disease (AD) dating back from 2002. The results of the collaboration shall allow to study the role of specific forms of the key Alzheimer protein amyloid beta, and related technology, as targets for new therapeutic avenues for AD. Based on the technology and products provided by Innogenetics and Inserm, Sanofi will evaluate different products against diverse forms of the beta protein in a passive immunization program. In return for providing Sanofi-aventis access to their technology and services, Innogenetics and Inserm-Transfert will receive upfront and research fees.
In the event Sanofi-aventis exercises its license option, Innogenetics and Inserm-Transfert will be entitled to milestone payments and royalties on future sales of therapeutic products resulting from this collaboration.
Financial terms of the agreement were not disclosed.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
From bacteria to electricity: The future of green energy

Cube Biotech acquires IBA Lifesciences - Two leading innovators of biotech join forces

Next-generation immunotherapy offers new hope for beating brain cancer
Ringing the changes 'opens the road to new medicines'
European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody
POC immunoassay for hCG
Novartis gains exclusive rights to Debio 025, an antiviral agent as potential first-in-class hepatitis C therapy - Novartis to make upfront payment to Debiopharm Group, with Debiopharm eligible for milestones and royalties on future sales
Merck & Co. Announces New Name for its Animal Health Division
Researchers discover new therapeutic approach for cardiorenal syndrome type 2
Magnetic nanoparticles navigate therapeutic genes through the body - PTB measures the pinpointed transport of therapeutics for cardiovascular diseases
